Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer
Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In t...
Uloženo v:
| Vydáno v: | Nature communications Ročník 12; číslo 1; s. 4310 - 22 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
14.07.2021
Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2041-1723, 2041-1723 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors.
Bone metastases are associated with poor prognosis in patients with breast cancer and limited therapeutic options. Here the authors exploit near-infrared light responsive macrophages for the tumor-selective delivery of oxaliplatin prodrug for chemo-photodynamic therapy of primary and bone metastatic breast cancer. |
|---|---|
| AbstractList | Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors. Bone metastases are associated with poor prognosis in patients with breast cancer and limited therapeutic options. Here the authors exploit near-infrared light responsive macrophages for the tumor-selective delivery of oxaliplatin prodrug for chemo-photodynamic therapy of primary and bone metastatic breast cancer. Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors.Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors. Bone metastases are associated with poor prognosis in patients with breast cancer and limited therapeutic options. Here the authors exploit near-infrared light responsive macrophages for the tumor-selective delivery of oxaliplatin prodrug for chemo-photodynamic therapy of primary and bone metastatic breast cancer. Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors. Bone metastases are associated with poor prognosis in patients with breast cancer and limited therapeutic options. Here the authors exploit near-infrared light responsive macrophages for the tumor-selective delivery of oxaliplatin prodrug for chemo-photodynamic therapy of primary and bone metastatic breast cancer. Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors. |
| ArticleNumber | 4310 |
| Author | Huang, Yanjuan Ren, Lingling Wei, Qin Jiang, Jingwen Zhao, Chunshun Xu, Xiaoyu Huang, Zeqian Dai, Xiuling Shen, Yifeng Guan, Zilin Luo, Yong Jiang, Yali Liu, Di Xiao, Zhanghong |
| Author_xml | – sequence: 1 givenname: Yanjuan surname: Huang fullname: Huang, Yanjuan organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 2 givenname: Zilin surname: Guan fullname: Guan, Zilin organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 3 givenname: Xiuling surname: Dai fullname: Dai, Xiuling organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 4 givenname: Yifeng surname: Shen fullname: Shen, Yifeng organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 5 givenname: Qin surname: Wei fullname: Wei, Qin organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 6 givenname: Lingling surname: Ren fullname: Ren, Lingling organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 7 givenname: Jingwen surname: Jiang fullname: Jiang, Jingwen organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 8 givenname: Zhanghong surname: Xiao fullname: Xiao, Zhanghong organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 9 givenname: Yali surname: Jiang fullname: Jiang, Yali organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 10 givenname: Di surname: Liu fullname: Liu, Di organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 11 givenname: Zeqian surname: Huang fullname: Huang, Zeqian organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 12 givenname: Xiaoyu surname: Xu fullname: Xu, Xiaoyu organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 13 givenname: Yong surname: Luo fullname: Luo, Yong organization: School of Pharmaceutical Sciences, Sun Yat-sen University – sequence: 14 givenname: Chunshun orcidid: 0000-0002-0574-7483 surname: Zhao fullname: Zhao, Chunshun email: zhaocs@mail.sysu.edu.cn organization: School of Pharmaceutical Sciences, Sun Yat-sen University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34262026$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuFDEQHKEg8iA_wAFZ4sJlwK95XZBQFEKkSFzgbPV42jNezdiL7V1p_4JPxptdQpJDfLHdXVWudvd5ceK8w6J4x-gnRkX7OUom66aknJVcVrUs6avijFPJStZwcfLofFpcxriieYmOtVK-KU6F5DWnvD4r_ly70TrEgANZQAe_nmDESCAShxBK60yAfXK245QI6GS3kPJ9CJuRbFEnHyIxPhA94eLL9eSTH3YOFqtJmjDAeke8IetgFwg7Am4gfa6ELJggJkgZ1gfMR6LBaQxvi9cG5oiXx_2i-PXt-ufV9_Lux83t1de7Ute0TuWgRQcNayqmO9PTTlBmKln1WjYoO84ENZJLLoYGa9bpDjsmWKXBtAap0EZcFLcH3cHDSh3tKQ9W3Qd8GBWE7G5GVdeM04oaFDWVNetbmSNdKwcYjAaNWevLQWu96RccNLoUYH4i-jTj7KRGv1UtbykXLAt8PAoE_3uDManFRo3zDA79JipeVdlBW4k2Qz88g678Jrj8VXsUk4wxWWXU-8eOHqz8a3wG8AMgtzzGgOYBwqjaD5g6DJjKA6buB0zRTGqfkbTdt9Dvq7Lzy1RxoMb8jhsx_Lf9Ausv4brmfA |
| CitedBy_id | crossref_primary_10_1016_j_bioactmat_2022_10_028 crossref_primary_10_1016_j_phymed_2023_155257 crossref_primary_10_1016_j_omto_2022_02_003 crossref_primary_10_1016_j_ejmech_2022_114120 crossref_primary_10_1016_j_intimp_2025_115237 crossref_primary_10_3389_fchem_2022_1088823 crossref_primary_10_1002_smtd_202200925 crossref_primary_10_1039_D2BM01621D crossref_primary_10_1088_1748_605X_ac4c8b crossref_primary_10_1016_j_carbpol_2022_120264 crossref_primary_10_1038_s41419_024_06616_7 crossref_primary_10_1016_j_nantod_2022_101543 crossref_primary_10_1038_s41417_023_00600_7 crossref_primary_10_1016_j_addr_2022_114380 crossref_primary_10_1007_s11051_023_05813_3 crossref_primary_10_1016_j_actbio_2024_07_042 crossref_primary_10_1038_s41467_025_56637_9 crossref_primary_10_3389_fimmu_2023_1199631 crossref_primary_10_1002_adma_202409590 crossref_primary_10_3233_THC_240831 crossref_primary_10_1016_j_omto_2022_12_009 crossref_primary_10_1002_EXP_20210106 crossref_primary_10_1002_adma_202207787 crossref_primary_10_1016_j_cej_2022_134783 crossref_primary_10_1002_adhm_202400030 crossref_primary_10_1002_adma_202211485 crossref_primary_10_1016_j_jconrel_2024_07_067 crossref_primary_10_1038_s41392_022_01136_2 crossref_primary_10_1002_advs_202206393 crossref_primary_10_1080_09553002_2022_2110310 crossref_primary_10_1021_jacs_5c02587 crossref_primary_10_1016_j_cej_2024_150153 crossref_primary_10_1002_adma_202209799 crossref_primary_10_1016_j_cclet_2023_108346 crossref_primary_10_1002_smll_202107787 crossref_primary_10_1038_s41467_024_53010_0 crossref_primary_10_1007_s40005_025_00754_6 crossref_primary_10_1186_s13046_025_03359_x crossref_primary_10_1016_j_bioactmat_2024_04_004 crossref_primary_10_1016_j_ccr_2024_215796 crossref_primary_10_1016_j_jconrel_2024_02_030 crossref_primary_10_1016_j_nantod_2023_102109 crossref_primary_10_1016_j_actbio_2025_04_023 crossref_primary_10_1002_bmm2_12112 crossref_primary_10_1016_j_addr_2023_114773 crossref_primary_10_3390_mi15050664 crossref_primary_10_1002_EXP_20210166 crossref_primary_10_3389_fbioe_2022_867164 crossref_primary_10_1002_mabi_202300093 crossref_primary_10_1002_adhm_202405061 crossref_primary_10_1016_j_cclet_2025_111013 crossref_primary_10_1002_EXP_20220124 crossref_primary_10_1002_smll_202309994 crossref_primary_10_1016_j_ccr_2023_215624 crossref_primary_10_1002_smll_202307694 crossref_primary_10_1016_j_biomaterials_2025_123620 crossref_primary_10_3389_fimmu_2021_783305 crossref_primary_10_1002_adhm_202303683 crossref_primary_10_1016_j_jbo_2024_100598 crossref_primary_10_1016_j_addr_2022_114585 crossref_primary_10_1016_j_lfs_2023_121917 crossref_primary_10_1016_j_biomaterials_2022_121433 crossref_primary_10_1111_imr_13231 crossref_primary_10_1002_anie_202214586 crossref_primary_10_1016_j_cej_2024_154506 crossref_primary_10_1002_advs_202308124 crossref_primary_10_3389_fimmu_2022_840029 crossref_primary_10_1016_j_ultsonch_2024_106928 crossref_primary_10_1021_jacs_2c07872 crossref_primary_10_1016_j_jconrel_2025_113679 crossref_primary_10_1016_j_biopha_2024_116930 crossref_primary_10_1016_j_carbpol_2024_122637 crossref_primary_10_1002_smll_202403422 crossref_primary_10_1016_j_ijpharm_2023_122755 crossref_primary_10_1016_j_cej_2024_155024 crossref_primary_10_3389_fimmu_2022_1026173 crossref_primary_10_1080_17425247_2024_2318460 crossref_primary_10_1016_j_nantod_2022_101732 crossref_primary_10_1038_s41467_024_50020_w crossref_primary_10_1002_smll_202305708 crossref_primary_10_1016_j_biomaterials_2023_122257 crossref_primary_10_3390_molecules30183726 crossref_primary_10_1016_j_biomaterials_2025_123107 crossref_primary_10_2147_IJN_S496456 crossref_primary_10_1088_1748_605X_aca736 crossref_primary_10_1002_adma_202416481 crossref_primary_10_1016_j_bios_2025_117559 crossref_primary_10_3390_pharmaceutics16121491 crossref_primary_10_1016_j_jconrel_2023_08_023 crossref_primary_10_1016_j_jconrel_2025_114155 crossref_primary_10_1016_j_nantod_2024_102423 crossref_primary_10_1016_j_biomaterials_2023_122396 crossref_primary_10_3390_biomimetics8070553 crossref_primary_10_1038_s41420_024_02236_4 crossref_primary_10_1016_j_cej_2025_162865 crossref_primary_10_34133_bmr_0015 crossref_primary_10_1016_j_apsb_2023_05_016 crossref_primary_10_1016_j_ccr_2024_216328 crossref_primary_10_1021_acsanm_5c02778 crossref_primary_10_2147_IJN_S491573 crossref_primary_10_1016_j_jconrel_2025_113851 crossref_primary_10_1136_jitc_2022_004936 crossref_primary_10_1016_j_jconrel_2022_06_006 crossref_primary_10_3389_fendo_2023_1260491 crossref_primary_10_3389_fonc_2021_786913 crossref_primary_10_3788_AOSOL250470 crossref_primary_10_1002_ange_202214586 crossref_primary_10_3390_nano11112790 crossref_primary_10_1002_adfm_202311857 crossref_primary_10_1186_s40824_023_00458_8 crossref_primary_10_1002_adma_202307785 crossref_primary_10_1002_smll_202308639 crossref_primary_10_1016_j_jconrel_2025_01_051 |
| Cites_doi | 10.1038/nrc3180 10.1038/nrc867 10.1038/nnano.2017.54 10.1038/nri2591 10.1016/j.biocel.2018.01.003 10.1021/nl072209h 10.1016/j.biotechadv.2019.01.006 10.1186/bcr2781 10.1002/anie.201804882 10.1016/j.omtm.2016.12.006 10.1038/nri2216 10.7150/thno.18069 10.1021/acs.nanolett.7b02330 10.1038/s41467-019-09760-3 10.1038/s41467-019-12771-9 10.7150/thno.35343 10.1126/science.aaa8172 10.1016/j.jconrel.2017.08.024 10.1038/s41467-018-04607-9 10.1002/adfm.201500061 10.1021/acsami.6b15444 10.1002/adfm.201906623 10.1016/j.bcp.2017.09.006 10.1038/s41467-018-04605-x 10.1038/s41467-017-01651-9 10.1016/j.jconrel.2012.06.004 10.1038/nature10673 10.1021/acsnano.8b07045 10.1158/1078-0432.CCR-07-2223 10.1038/nri3902 10.1021/acsnano.7b00715 10.1038/nri3070 10.1002/adma.201707112 10.1016/j.ejca.2006.01.003 10.1038/nrc.2016.44 10.1002/adma.201805888 10.1002/pros.20909 10.1016/j.jconrel.2019.12.043 10.1158/0008-5472.CAN-17-1225 10.1517/17425247.2011.559457 10.1002/adfm.201701093 10.1038/nmat3792 10.1038/cr.2015.68 10.1038/natrevmats.2016.14 10.1002/adma.201805557 10.1016/j.coph.2015.04.004 10.1002/adma.201903242 10.1038/ncomms12499 10.1158/1078-0432.CCR-06-0931 10.1039/C7NR00962C 10.1021/acsnano.9b00097 10.1002/adma.201807211 10.1038/nrclinonc.2015.209 10.1016/S0006-3495(95)80402-9 10.1038/s41467-019-13993-7 10.1002/smll.202007882 10.1080/2162402X.2018.1442169 10.1038/s41467-016-0009-6 10.1038/s41467-018-07882-8 10.1080/17425247.2017.1254614 10.1002/adfm.202011171 10.1016/j.addr.2019.12.001 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA |
| DOI | 10.1038/s41467-021-24564-0 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (via ProQuest) ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2041-1723 |
| EndPage | 22 |
| ExternalDocumentID | oai_doaj_org_article_6612050fe360461b84661984dadfcace PMC8280231 34262026 10_1038_s41467_021_24564_0 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 81973256/H3008 funderid: https://doi.org/10.13039/501100001809 – fundername: China Postdoctoral Science Foundation grantid: 2020M683145 funderid: https://doi.org/10.13039/501100002858 – fundername: ; grantid: 2020M683145 – fundername: ; grantid: 81973256/H3008 |
| GroupedDBID | --- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LK8 M1P M48 M7P M~E NAO O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX AFFHD CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 5PM |
| ID | FETCH-LOGICAL-c606t-dc39a71751c9fb09301f545bc47e492130f42423d7e619c9e91315caf8fe03cf3 |
| IEDL.DBID | P5Z |
| ISICitedReferencesCount | 145 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000675628800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2041-1723 |
| IngestDate | Fri Oct 03 12:40:33 EDT 2025 Tue Nov 04 02:00:17 EST 2025 Sun Nov 09 12:54:47 EST 2025 Tue Oct 07 06:52:05 EDT 2025 Mon Jul 21 05:39:54 EDT 2025 Tue Nov 18 21:21:16 EST 2025 Sat Nov 29 06:29:26 EST 2025 Fri Feb 21 02:38:58 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2021. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c606t-dc39a71751c9fb09301f545bc47e492130f42423d7e619c9e91315caf8fe03cf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0574-7483 |
| OpenAccessLink | https://www.proquest.com/docview/2551411145?pq-origsite=%requestingapplication% |
| PMID | 34262026 |
| PQID | 2551411145 |
| PQPubID | 546298 |
| PageCount | 22 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6612050fe360461b84661984dadfcace pubmedcentral_primary_oai_pubmedcentral_nih_gov_8280231 proquest_miscellaneous_2552058538 proquest_journals_2551411145 pubmed_primary_34262026 crossref_primary_10_1038_s41467_021_24564_0 crossref_citationtrail_10_1038_s41467_021_24564_0 springer_journals_10_1038_s41467_021_24564_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-14 |
| PublicationDateYYYYMMDD | 2021-07-14 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature communications |
| PublicationTitleAbbrev | Nat Commun |
| PublicationTitleAlternate | Nat Commun |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Mundy (CR47) 2002; 2 Chen, Sosnoski, Mastro (CR5) 2010; 12 Turley, Cremasco, Astarita (CR17) 2015; 15 Huang (CR54) 2020; 319 Clément-Demange, Clézardin (CR3) 2015; 22 Zhang (CR15) 2018; 30 Tiet, Berlin (CR30) 2017; 145 Batrakova, Gendelman, Kabanov (CR33) 2011; 8 CR35 CR34 Smyth, Ngiow, Ribas, Teng (CR16) 2016; 13 Sun (CR52) 2019; 13 Schroeder (CR24) 2012; 12 Xu (CR18) 2017; 11 Zhang (CR38) 2018; 30 Duan, Chan, Lin (CR19) 2019; 58 Shi, Pamer (CR39) 2011; 11 Mellman, Coukos, Dranoff (CR9) 2011; 480 He (CR27) 2017; 17 Levine, Miskin, Wonnacott, Keir (CR36) 2017; 4 Huang (CR48) 2019; 10 CR6 Zitvogel, Apetoh, Ghiringhelli, Kroemer (CR21) 2008; 8 Li (CR57) 2019; 31 He (CR60) 2016; 7 Lu (CR59) 2017; 8 CR45 Ross (CR1) 2017; 77 Xue (CR26) 2017; 12 Thorpe, Toner, Ezzell, Tompkins, Yarmush (CR43) 1995; 68 Wilhelm (CR28) 2016; 1 Xiao (CR41) 2012; 163 Nam (CR22) 2018; 9 Brook, Brook, Dharmarajan, Dass, Chan (CR4) 2018; 96 Sica, Schioppa, Mantovani, Allavena (CR44) 2006; 42 Song (CR14) 2018; 9 Zhou (CR13) 2019; 31 Sun, Wang, Gao, Hu, Liu (CR32) 2015; 25 Zhao (CR53) 2017; 9 Huang (CR62) 2019; 9 CR58 Yue (CR12) 2019; 10 Im (CR20) 2018; 13 Gao (CR31) 2017; 9 Choi (CR37) 2007; 7 Meads, Hazlehurst, Dalton (CR7) 2008; 14 CR50 Kelly, O’neill (CR56) 2015; 25 Coleman (CR2) 2006; 12 Liu, Wu, Choi, Berkman (CR42) 2009; 69 Wang (CR51) 2020; 11 Croucher, McDonald, Martin (CR8) 2016; 16 Dong, Chu, Wang (CR40) 2017; 7 He (CR63) 2017; 264 Sharma, Allison (CR10) 2015; 348 CR23 Chen (CR49) 2019; 30 CR61 Chauhan, Jain (CR25) 2013; 12 Lang (CR46) 2017; 27 Russell, VanderVen, Glennie, Mwandumba, Heyderman (CR55) 2009; 9 Singh, Mitragotri (CR29) 2020; 42 Phuengkham, Song, Lim (CR11) 2019; 31 CX Li (24564_CR57) 2019; 31 MB Meads (24564_CR7) 2008; 14 J Xu (24564_CR18) 2017; 11 MJ Smyth (24564_CR16) 2016; 13 L Clément-Demange (24564_CR3) 2015; 22 M-R Choi (24564_CR37) 2007; 7 RE Coleman (24564_CR2) 2006; 12 W Yue (24564_CR12) 2019; 10 X Dong (24564_CR40) 2017; 7 X Zhang (24564_CR15) 2018; 30 PI Croucher (24564_CR8) 2016; 16 C Shi (24564_CR39) 2011; 11 Y He (24564_CR63) 2017; 264 24564_CR50 W Chen (24564_CR49) 2019; 30 VP Chauhan (24564_CR25) 2013; 12 J Lu (24564_CR59) 2017; 8 B Singh (24564_CR29) 2020; 42 T Liu (24564_CR42) 2009; 69 24564_CR58 W Song (24564_CR14) 2018; 9 WP Thorpe (24564_CR43) 1995; 68 X Duan (24564_CR19) 2019; 58 L Huang (24564_CR48) 2019; 10 J Xue (24564_CR26) 2017; 12 X He (24564_CR27) 2017; 17 C He (24564_CR60) 2016; 7 24564_CR61 24564_CR23 N Brook (24564_CR4) 2018; 96 S Im (24564_CR20) 2018; 13 M Gao (24564_CR31) 2017; 9 S Wilhelm (24564_CR28) 2016; 1 T Lang (24564_CR46) 2017; 27 Y Huang (24564_CR54) 2020; 319 I Mellman (24564_CR9) 2011; 480 B Kelly (24564_CR56) 2015; 25 Y-P Zhao (24564_CR53) 2017; 9 L Zitvogel (24564_CR21) 2008; 8 A Schroeder (24564_CR24) 2012; 12 W Zhang (24564_CR38) 2018; 30 Y-C Chen (24564_CR5) 2010; 12 Z Huang (24564_CR62) 2019; 9 H Phuengkham (24564_CR11) 2019; 31 X Sun (24564_CR32) 2015; 25 24564_CR35 H Xiao (24564_CR41) 2012; 163 24564_CR34 BL Levine (24564_CR36) 2017; 4 SJ Turley (24564_CR17) 2015; 15 EV Batrakova (24564_CR33) 2011; 8 P Tiet (24564_CR30) 2017; 145 G-H Nam (24564_CR22) 2018; 9 P Sharma (24564_CR10) 2015; 348 24564_CR6 F Zhou (24564_CR13) 2019; 31 H Wang (24564_CR51) 2020; 11 MH Ross (24564_CR1) 2017; 77 W Sun (24564_CR52) 2019; 13 DG Russell (24564_CR55) 2009; 9 A Sica (24564_CR44) 2006; 42 24564_CR45 GR Mundy (24564_CR47) 2002; 2 |
| References_xml | – ident: CR45 – volume: 12 start-page: 39 year: 2012 end-page: 50 ident: CR24 article-title: Treating metastatic cancer with nanotechnology publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3180 – volume: 2 start-page: 584 year: 2002 end-page: 593 ident: CR47 article-title: Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities publication-title: Nat. Rev. Cancer doi: 10.1038/nrc867 – volume: 12 start-page: 692 year: 2017 end-page: 700 ident: CR26 article-title: Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence publication-title: Nat. Nanotechnol. doi: 10.1038/nnano.2017.54 – volume: 9 start-page: 594 year: 2009 end-page: 600 ident: CR55 article-title: The macrophage marches on its phagosome: dynamic assays of phagosome function publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2591 – volume: 96 start-page: 63 year: 2018 end-page: 78 ident: CR4 article-title: Breast cancer bone metastases: pathogenesis and therapeutic targets publication-title: Int. J. Biochem. Cell Biol. doi: 10.1016/j.biocel.2018.01.003 – volume: 7 start-page: 3759 year: 2007 end-page: 3765 ident: CR37 article-title: A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors publication-title: Nano Lett. doi: 10.1021/nl072209h – volume: 42 start-page: 107339 year: 2020 ident: CR29 article-title: Harnessing cells to deliver nanoparticle drugs to treat cancer publication-title: Biotechnol. Adv. doi: 10.1016/j.biotechadv.2019.01.006 – volume: 12 year: 2010 ident: CR5 article-title: Breast cancer metastasis to the bone: mechanisms of bone loss publication-title: Breast Cancer Res. doi: 10.1186/bcr2781 – volume: 58 start-page: 670 year: 2019 end-page: 680 ident: CR19 article-title: Nanoparticle‐mediated immunogenic cell death enables and potentiates cancer immunotherapy publication-title: Angew. Chem. Int. Ed. doi: 10.1002/anie.201804882 – ident: CR35 – volume: 4 start-page: 92 year: 2017 end-page: 101 ident: CR36 article-title: Global manufacturing of CAR T cell therapy publication-title: Mol. Ther. Methods Clin. Dev. doi: 10.1016/j.omtm.2016.12.006 – ident: CR61 – ident: CR58 – volume: 8 start-page: 59 year: 2008 end-page: 73 ident: CR21 article-title: Immunological aspects of cancer chemotherapy publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2216 – volume: 7 start-page: 751 year: 2017 end-page: 763 ident: CR40 article-title: Leukocyte-mediated delivery of nanotherapeutics in inflammatory and tumor sites publication-title: Theranostics doi: 10.7150/thno.18069 – volume: 17 start-page: 5546 year: 2017 end-page: 5554 ident: CR27 article-title: Inflammatory monocytes loading protease-sensitive nanoparticles enable lung metastasis targeting and intelligent drug release for anti-metastasis therapy publication-title: Nano Lett. doi: 10.1021/acs.nanolett.7b02330 – volume: 10 year: 2019 ident: CR12 article-title: Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice publication-title: Nat. Commun. doi: 10.1038/s41467-019-09760-3 – volume: 10 start-page: 1 year: 2019 end-page: 15 ident: CR48 article-title: Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy publication-title: Nat. Commun. doi: 10.1038/s41467-019-12771-9 – volume: 9 start-page: 5542 year: 2019 end-page: 5557 ident: CR62 article-title: Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor publication-title: Theranostics doi: 10.7150/thno.35343 – volume: 348 start-page: 56 year: 2015 end-page: 61 ident: CR10 article-title: The future of immune checkpoint therapy publication-title: Science doi: 10.1126/science.aaa8172 – volume: 264 start-page: 76 year: 2017 end-page: 88 ident: CR63 article-title: Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer publication-title: J. Control. Release doi: 10.1016/j.jconrel.2017.08.024 – volume: 9 year: 2018 ident: CR22 article-title: Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer publication-title: Nat. Commun. doi: 10.1038/s41467-018-04607-9 – volume: 25 start-page: 2386 year: 2015 end-page: 2394 ident: CR32 article-title: Remotely controlled red blood cell carriers for cancer targeting and near‐infrared light‐triggered drug release in combined photothermal–chemotherapy publication-title: Adv. Funct. Mater. doi: 10.1002/adfm.201500061 – volume: 9 start-page: 5855 year: 2017 end-page: 5863 ident: CR31 article-title: Photosensitizer decorated red blood cells as an ultrasensitive light-responsive drug delivery system publication-title: ACS Appl. Mater. Interfaces doi: 10.1021/acsami.6b15444 – ident: CR50 – volume: 30 start-page: 1906623 year: 2019 ident: CR49 article-title: Combination of bacterial‐photothermal therapy with an anti‐PD‐1 peptide depot for enhanced immunity against advanced cancer publication-title: Adv. Funct. Mater. doi: 10.1002/adfm.201906623 – volume: 145 start-page: 18 year: 2017 end-page: 26 ident: CR30 article-title: Exploiting homing abilities of cell carriers: targeted delivery of nanoparticles for cancer therapy publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2017.09.006 – volume: 11 start-page: 1 year: 2020 end-page: 14 ident: CR51 article-title: Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors publication-title: Nat. Commun. – volume: 9 year: 2018 ident: CR14 article-title: Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap publication-title: Nat. Commun. doi: 10.1038/s41467-018-04605-x – volume: 8 start-page: 1 year: 2017 end-page: 14 ident: CR59 article-title: Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression publication-title: Nat. Commun. doi: 10.1038/s41467-017-01651-9 – volume: 163 start-page: 304 year: 2012 end-page: 314 ident: CR41 article-title: Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy publication-title: J. Control. Release doi: 10.1016/j.jconrel.2012.06.004 – volume: 480 start-page: 480 year: 2011 end-page: 489 ident: CR9 article-title: Cancer immunotherapy comes of age publication-title: Nature doi: 10.1038/nature10673 – volume: 13 start-page: 476 year: 2018 end-page: 488 ident: CR20 article-title: Hypoxia-triggered transforming immunomodulator for cancer immunotherapy via photodynamically enhanced antigen presentation of dendritic cell publication-title: ACS Nano doi: 10.1021/acsnano.8b07045 – volume: 14 start-page: 2519 year: 2008 end-page: 2526 ident: CR7 article-title: The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-2223 – volume: 15 start-page: 669 year: 2015 end-page: 682 ident: CR17 article-title: Immunological hallmarks of stromal cells in the tumour microenvironment publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3902 – volume: 11 start-page: 4463 year: 2017 end-page: 4474 ident: CR18 article-title: Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer publication-title: ACS Nano doi: 10.1021/acsnano.7b00715 – volume: 11 start-page: 762 year: 2011 end-page: 774 ident: CR39 article-title: Monocyte recruitment during infection and inflammation publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3070 – volume: 30 start-page: 1707112 year: 2018 ident: CR15 article-title: PD‐1 blockade cellular vesicles for cancer immunotherapy publication-title: Adv. Mater. doi: 10.1002/adma.201707112 – volume: 42 start-page: 717 year: 2006 end-page: 727 ident: CR44 article-title: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2006.01.003 – volume: 16 start-page: 373 year: 2016 end-page: 386 ident: CR8 article-title: Bone metastasis: the importance of the neighbourhood publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.44 – volume: 31 start-page: 1805888 year: 2019 ident: CR13 article-title: Tumor microenvironment‐activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade publication-title: Adv. Mater. doi: 10.1002/adma.201805888 – ident: CR6 – volume: 69 start-page: 585 year: 2009 end-page: 594 ident: CR42 article-title: In vitro targeted photodynamic therapy with a pyropheophorbide‐a conjugated inhibitor of prostate‐specific membrane antigen publication-title: Prostate doi: 10.1002/pros.20909 – volume: 319 start-page: 119 year: 2020 end-page: 134 ident: CR54 article-title: A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways publication-title: J. Control. Release doi: 10.1016/j.jconrel.2019.12.043 – volume: 77 start-page: 6299 year: 2017 end-page: 6312 ident: CR1 article-title: Bone-induced expression of integrin β3 enables targeted nanotherapy of breast cancer metastases publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-1225 – ident: CR23 – volume: 8 start-page: 415 year: 2011 end-page: 433 ident: CR33 article-title: Cell-mediated drug delivery publication-title: Expert Opin. Drug Deliv. doi: 10.1517/17425247.2011.559457 – volume: 27 start-page: 1701093 year: 2017 ident: CR46 article-title: Ly6Chi monocytes delivering pH‐sensitive micelle loading paclitaxel improve targeting therapy of metastatic breast cancer publication-title: Adv. Funct. Mater. doi: 10.1002/adfm.201701093 – volume: 12 start-page: 958 year: 2013 end-page: 962 ident: CR25 article-title: Strategies for advancing cancer nanomedicine publication-title: Nat. Mater. doi: 10.1038/nmat3792 – volume: 25 start-page: 771 year: 2015 end-page: 784 ident: CR56 article-title: Metabolic reprogramming in macrophages and dendritic cells in innate immunity publication-title: Cell Res. doi: 10.1038/cr.2015.68 – volume: 1 start-page: 1 year: 2016 end-page: 12 ident: CR28 article-title: Analysis of nanoparticle delivery to tumours publication-title: Nat. Rev. Mater. doi: 10.1038/natrevmats.2016.14 – volume: 30 start-page: 1805557 year: 2018 ident: CR38 article-title: Nanoparticle‐laden macrophages for tumor‐tropic drug delivery publication-title: Adv. Mater. doi: 10.1002/adma.201805557 – volume: 22 start-page: 79 year: 2015 end-page: 86 ident: CR3 article-title: Emerging therapies in bone metastasis publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2015.04.004 – volume: 31 start-page: 1903242 year: 2019 ident: CR11 article-title: A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy publication-title: Adv. Mater. doi: 10.1002/adma.201903242 – ident: CR34 – volume: 7 start-page: 1 year: 2016 end-page: 12 ident: CR60 article-title: Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy publication-title: Nat. Commun. doi: 10.1038/ncomms12499 – volume: 12 start-page: 6243s year: 2006 end-page: 6249s ident: CR2 article-title: Clinical features of metastatic bone disease and risk of skeletal morbidity publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-0931 – volume: 9 start-page: 6264 year: 2017 end-page: 6277 ident: CR53 article-title: Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption publication-title: Nanoscale doi: 10.1039/C7NR00962C – volume: 13 start-page: 7556 year: 2019 end-page: 7567 ident: CR52 article-title: Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis publication-title: ACS Nano doi: 10.1021/acsnano.9b00097 – volume: 31 start-page: 1807211 year: 2019 ident: CR57 article-title: Artificially reprogrammed macrophages as tumor‐tropic immunosuppression‐resistant biologics to realize therapeutics production and immune activation publication-title: Adv. Mater. doi: 10.1002/adma.201807211 – volume: 13 start-page: 143 year: 2016 end-page: 158 ident: CR16 article-title: Combination cancer immunotherapies tailored to the tumour microenvironment publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2015.209 – volume: 68 start-page: 2198 year: 1995 end-page: 2206 ident: CR43 article-title: Dynamics of photoinduced cell plasma membrane injury publication-title: Biophys. J. doi: 10.1016/S0006-3495(95)80402-9 – volume: 11 start-page: 1 year: 2020 ident: 24564_CR51 publication-title: Nat. Commun. doi: 10.1038/s41467-019-13993-7 – volume: 7 start-page: 751 year: 2017 ident: 24564_CR40 publication-title: Theranostics doi: 10.7150/thno.18069 – ident: 24564_CR61 doi: 10.1002/smll.202007882 – ident: 24564_CR50 doi: 10.1080/2162402X.2018.1442169 – volume: 13 start-page: 143 year: 2016 ident: 24564_CR16 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2015.209 – volume: 14 start-page: 2519 year: 2008 ident: 24564_CR7 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-2223 – volume: 68 start-page: 2198 year: 1995 ident: 24564_CR43 publication-title: Biophys. J. doi: 10.1016/S0006-3495(95)80402-9 – volume: 25 start-page: 771 year: 2015 ident: 24564_CR56 publication-title: Cell Res. doi: 10.1038/cr.2015.68 – volume: 9 start-page: 5542 year: 2019 ident: 24564_CR62 publication-title: Theranostics doi: 10.7150/thno.35343 – volume: 12 start-page: 692 year: 2017 ident: 24564_CR26 publication-title: Nat. Nanotechnol. doi: 10.1038/nnano.2017.54 – volume: 11 start-page: 4463 year: 2017 ident: 24564_CR18 publication-title: ACS Nano doi: 10.1021/acsnano.7b00715 – volume: 163 start-page: 304 year: 2012 ident: 24564_CR41 publication-title: J. Control. Release doi: 10.1016/j.jconrel.2012.06.004 – volume: 30 start-page: 1805557 year: 2018 ident: 24564_CR38 publication-title: Adv. Mater. doi: 10.1002/adma.201805557 – volume: 25 start-page: 2386 year: 2015 ident: 24564_CR32 publication-title: Adv. Funct. Mater. doi: 10.1002/adfm.201500061 – volume: 2 start-page: 584 year: 2002 ident: 24564_CR47 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc867 – volume: 16 start-page: 373 year: 2016 ident: 24564_CR8 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.44 – volume: 8 start-page: 1 year: 2017 ident: 24564_CR59 publication-title: Nat. Commun. doi: 10.1038/s41467-016-0009-6 – volume: 27 start-page: 1701093 year: 2017 ident: 24564_CR46 publication-title: Adv. Funct. Mater. doi: 10.1002/adfm.201701093 – volume: 96 start-page: 63 year: 2018 ident: 24564_CR4 publication-title: Int. J. Biochem. Cell Biol. doi: 10.1016/j.biocel.2018.01.003 – volume: 9 start-page: 6264 year: 2017 ident: 24564_CR53 publication-title: Nanoscale doi: 10.1039/C7NR00962C – volume: 8 start-page: 59 year: 2008 ident: 24564_CR21 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2216 – volume: 69 start-page: 585 year: 2009 ident: 24564_CR42 publication-title: Prostate doi: 10.1002/pros.20909 – volume: 480 start-page: 480 year: 2011 ident: 24564_CR9 publication-title: Nature doi: 10.1038/nature10673 – volume: 13 start-page: 476 year: 2018 ident: 24564_CR20 publication-title: ACS Nano doi: 10.1021/acsnano.8b07045 – volume: 7 start-page: 3759 year: 2007 ident: 24564_CR37 publication-title: Nano Lett. doi: 10.1021/nl072209h – volume: 31 start-page: 1903242 year: 2019 ident: 24564_CR11 publication-title: Adv. Mater. doi: 10.1002/adma.201903242 – ident: 24564_CR23 – volume: 9 year: 2018 ident: 24564_CR22 publication-title: Nat. Commun. doi: 10.1038/s41467-018-04607-9 – volume: 12 start-page: 6243s year: 2006 ident: 24564_CR2 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-0931 – volume: 17 start-page: 5546 year: 2017 ident: 24564_CR27 publication-title: Nano Lett. doi: 10.1021/acs.nanolett.7b02330 – volume: 319 start-page: 119 year: 2020 ident: 24564_CR54 publication-title: J. Control. Release doi: 10.1016/j.jconrel.2019.12.043 – volume: 9 year: 2018 ident: 24564_CR14 publication-title: Nat. Commun. doi: 10.1038/s41467-018-04605-x – volume: 8 start-page: 415 year: 2011 ident: 24564_CR33 publication-title: Expert Opin. Drug Deliv. doi: 10.1517/17425247.2011.559457 – volume: 31 start-page: 1807211 year: 2019 ident: 24564_CR57 publication-title: Adv. Mater. doi: 10.1002/adma.201807211 – volume: 31 start-page: 1805888 year: 2019 ident: 24564_CR13 publication-title: Adv. Mater. doi: 10.1002/adma.201805888 – ident: 24564_CR35 – volume: 9 start-page: 5855 year: 2017 ident: 24564_CR31 publication-title: ACS Appl. Mater. Interfaces doi: 10.1021/acsami.6b15444 – ident: 24564_CR6 doi: 10.1021/acsnano.9b00097 – volume: 1 start-page: 1 year: 2016 ident: 24564_CR28 publication-title: Nat. Rev. Mater. – volume: 10 year: 2019 ident: 24564_CR12 publication-title: Nat. Commun. doi: 10.1038/s41467-019-09760-3 – volume: 7 start-page: 1 year: 2016 ident: 24564_CR60 publication-title: Nat. Commun. – volume: 10 start-page: 1 year: 2019 ident: 24564_CR48 publication-title: Nat. Commun. doi: 10.1038/s41467-018-07882-8 – volume: 22 start-page: 79 year: 2015 ident: 24564_CR3 publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2015.04.004 – volume: 12 start-page: 39 year: 2012 ident: 24564_CR24 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3180 – volume: 348 start-page: 56 year: 2015 ident: 24564_CR10 publication-title: Science doi: 10.1126/science.aaa8172 – volume: 12 start-page: 958 year: 2013 ident: 24564_CR25 publication-title: Nat. Mater. doi: 10.1038/nmat3792 – ident: 24564_CR34 doi: 10.1080/17425247.2017.1254614 – volume: 4 start-page: 92 year: 2017 ident: 24564_CR36 publication-title: Mol. Ther. Methods Clin. Dev. doi: 10.1016/j.omtm.2016.12.006 – volume: 15 start-page: 669 year: 2015 ident: 24564_CR17 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3902 – volume: 42 start-page: 107339 year: 2020 ident: 24564_CR29 publication-title: Biotechnol. Adv. doi: 10.1016/j.biotechadv.2019.01.006 – volume: 42 start-page: 717 year: 2006 ident: 24564_CR44 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2006.01.003 – volume: 9 start-page: 594 year: 2009 ident: 24564_CR55 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2591 – volume: 30 start-page: 1906623 year: 2019 ident: 24564_CR49 publication-title: Adv. Funct. Mater. doi: 10.1002/adfm.201906623 – volume: 13 start-page: 7556 year: 2019 ident: 24564_CR52 publication-title: ACS Nano doi: 10.1021/acsnano.9b00097 – volume: 58 start-page: 670 year: 2019 ident: 24564_CR19 publication-title: Angew. Chem. Int. Ed. doi: 10.1002/anie.201804882 – volume: 30 start-page: 1707112 year: 2018 ident: 24564_CR15 publication-title: Adv. Mater. doi: 10.1002/adma.201707112 – ident: 24564_CR58 doi: 10.1002/adfm.202011171 – volume: 264 start-page: 76 year: 2017 ident: 24564_CR63 publication-title: J. Control. Release doi: 10.1016/j.jconrel.2017.08.024 – volume: 145 start-page: 18 year: 2017 ident: 24564_CR30 publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2017.09.006 – volume: 12 year: 2010 ident: 24564_CR5 publication-title: Breast Cancer Res. doi: 10.1186/bcr2781 – ident: 24564_CR45 doi: 10.1016/j.addr.2019.12.001 – volume: 77 start-page: 6299 year: 2017 ident: 24564_CR1 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-1225 – volume: 11 start-page: 762 year: 2011 ident: 24564_CR39 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3070 |
| SSID | ssj0000391844 |
| Score | 2.653796 |
| Snippet | Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of... Bone metastases are associated with poor prognosis in patients with breast cancer and limited therapeutic options. Here the authors exploit near-infrared light... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4310 |
| SubjectTerms | 13/2 13/21 13/31 13/51 14/1 14/19 14/34 14/5 59/5 631/67/1344 631/67/1347 631/67/322/803 64/60 Animals Antitumor activity Apoptosis - drug effects B7-H1 Antigen - antagonists & inhibitors Bone cancer Bone Neoplasms - drug therapy Bone Neoplasms - immunology Bone Neoplasms - secondary Bone tumors Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - immunology Breast Neoplasms - pathology Cell death Cell Line, Tumor Cell Movement - drug effects Drug Carriers - chemistry Drug delivery Drug Delivery Systems Female Humanities and Social Sciences Humans I.R. radiation Immune Checkpoint Inhibitors - therapeutic use Immune response Immune system Immunogenic Cell Death - drug effects Immunogenicity Immunologic Memory - drug effects Immunotherapy Indoles - administration & dosage Indoles - chemistry Indoles - pharmacology Infrared Rays Macrophages Macrophages - chemistry Macrophages - transplantation Medical prognosis Metastases Metastasis multidisciplinary Nanomedicine Nanotechnology Near infrared radiation Organometallic Compounds - administration & dosage Organometallic Compounds - chemistry Organometallic Compounds - pharmacology Oxaliplatin Oxaliplatin - administration & dosage Oxaliplatin - chemistry Oxaliplatin - pharmacology Patients PD-L1 protein Phenotypes Photochemotherapy - methods Photodynamic therapy Photosensitizing Agents - administration & dosage Photosensitizing Agents - chemistry Photosensitizing Agents - pharmacology Prodrugs Prodrugs - administration & dosage Prodrugs - chemistry Prodrugs - pharmacology Quality of life Science Science (multidisciplinary) Survival Toxicity Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQCiQuiDdhF2QkbmBtYjtNfFwQK04rDiDtzfKTrrRNVklaaf8FP5kZOy1bnheujdu6ns-ebzrjbwh57ayqDDBfVreqYVJ4zqywhpmG-4iZK899ajbRnJ215-fq041WX1gTluWB88Idg__gZV3GIBaoDW7BXwLnb6U3PjrjAp6-wHpuBFPpDBYKQhc535IpRXs8ynQmYEUC5vokK_c8URLs_x3L_LVY8qeMaXJEp_fJvZlB0pM88wfkVugekju5p-T1I_JtqzAYPF0ZbNC1hCNjpGakHaCaAaIGLDqnlxiWU7zXsAG-6akf1l_pJv2JP1KgshTMuerZ1bKfep_71tN8W-ua9pFeZZkKajpPbd8FugqTwetJMMxipftEHSJqeEy-nH74_P4jm9suMAfRzMS8E8pAlFdXTkVbKjgCIvAs62QTpOLg9KJEFuabAJZwKqhKVLUzsY2hFC6KJ-Sgg-99RuhCNt5bwwEnwAy9tcAnIYKxZeSl99wWpNqaQLtZkxxbY1zqlBsXrc5m02A2ncymy4K82b1n_ql_Hf0OLbsbiWra6QXAmJ4xpv-FsYIcbXGh5y0-ao5cEzyFrAvyavcYNidmXEwX-nUaAx8MjKgtyNMMo91MROoFwBcFafYAtjfV_SfdxTIJgEOUjLJ9BXm7heKPaf15KZ7_j6U4JHc57iGUFpVH5GAa1uEFue0208U4vEyb8DvbljXj priority: 102 providerName: Directory of Open Access Journals |
| Title | Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer |
| URI | https://link.springer.com/article/10.1038/s41467-021-24564-0 https://www.ncbi.nlm.nih.gov/pubmed/34262026 https://www.proquest.com/docview/2551411145 https://www.proquest.com/docview/2552058538 https://pubmed.ncbi.nlm.nih.gov/PMC8280231 https://doaj.org/article/6612050fe360461b84661984dadfcace |
| Volume | 12 |
| WOSCitedRecordID | wos000675628800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: P5Z dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M7P dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: PIMPY dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYXZC48H4ElspI3MDaxHGa5IRYtCs4UEUIpMIl8nNbaZuUJK3Uf8FPZsZJuyqPvXDpIXZTu54Zf-MZf0PIK63ySALyZUmWp0zEhjMVK8lkyo3DyJXhxhebSCeTbDrNi-HArR3SKrc20RtqU2s8Iz_huLWDYork7fIHw6pRGF0dSmgckCNkSUDFLJLvuzMWZD_PhBjuyoRxdtIKbxkwLwEjfoKFe_uRp-3_G9b8M2Xyt7ip347O7_7vRO6ROwMQpe96yblPbtjqAbnVl6bcPCQ_t0SF1tCFxDpfM7A8LZUtrUA5GAhmg7nr9BK9e4rXI9YAWw01zeqCrn0soKWAiClIxaJmy1nd1WZTycVc0_7S14bWji57tgsqK0NVXVm6sJ3EW07QTWHCfEc1CmbziHw9P_vy_gMbqjcwDU5Rx4yOcwnOYhLp3KkwB0viAK4pLVIrcg57pxMI5kxqwYnTuc2jOEq0dJmzYaxd_JgcVvC7Twkdi9QYJTmIGwBMoxTAUnCEVOh4aAxXAYm2a1jqgdocK2xclj7EHmdlv-4lrHvp170MA_J6951hqtf2PkXR2PVEUm7_oG4uykHHS4A6PExCZ-Mx0tgrgHYws0wYaZyW2gbkeCsR5WAp2vJKHALyctcMOo6BG1nZeuX7wIsBWGUBedLL4W4ksS8pwMcBSfckdG-o-y3VfOZ5xMHZRva_gLzZyvLVsP79Vzy7fhbPyW2O6oXco-KYHHbNyr4gN_W6m7fNiByk09R_ZiNydHo2KT6P_DHICJNui5HXX2gpPn4qvv0CMN5LPg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VAoIL74ehwCLBCaza601sHxDiVbVqiTgUqTd3X24iNXawnaD8C34Jv5GZtZ0qPHrrgWu8cXY3M99-s_MCeKFVGkpkvv4gSWNfRIb7KlLSlzE3OXmuDDeu2UQ8GiVHR-mXDfjZ58JQWGWPiQ6oTanpjnyb09GOiikGb2fffOoaRd7VvoVGKxb7dvkdTbb6zd5H_H9fcr7z6fDDrt91FfA1kvXGNzpKJRoxg1CnuUKDPghzpBFKi9iKlCOm54JIhoktGhc6tWkYhQMt8yS3QaTzCN97CS4jjscUQhYfxas7Haq2ngjR5eYEUbJdC4dEFAdBHkbhB2vnn2sT8Ddu-2eI5m9-Wnf87dz83zbuFtzoiDZ712rGbdiwxR242rbeXN6FH30hRmvYVFIfszEia81kzQqcrI-KV1FsPjul2wtG6R8LpOWGmWp-whbO11EzZPwMpX5a-rNx2ZRmWcjpRLM2qW3JypzN2moeTBaGqbKwbGobSVlcOExRQkDDNCledQ--Xsh23IfNAn_3IbChiI1RkqM6IYE2SiHtRkNPBTkPjOHKg7CXmUx3pdupg8hp5kIIoiRr5SxDOcucnGWBB69W3-mWeu7o9ySKq5FUdNx9UFYnWYdhGVI5HgyC3EZDKtOvkLriyhJhpMm11NaDrV4Csw4J6-xM_Dx4vnqMGEaOKVnYcu7G4IuROCYePGjlfjWTyLVM4EMP4jWNWJvq-pNiMnZ10hPuqht68LrXnbNp_XsrHp2_imdwbffw80F2sDfafwzXOak21VkVW7DZVHP7BK7oRTOpq6cOGxgcX7RO_QKwsp-d |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jj9MwFLaGYREX9iUwgJHgBFETx2mSA0LAUDEaVPUA0ohL8DqtNE1Kkhb1X_B7-HW85yQdlWVuc-DauKntvu_5e34bIc-UzEIBzNeP0yzxeaSZLyMpfJEwbdFzpZl2zSaS8Tg9OsomO-RnnwuDYZW9TnSKWpcK78gHDI92ACaPB7YLi5jsj14vvvnYQQo9rX07jVZEDs36O5hv9auDffivnzM2ev_p3Qe_6zDgKyDuja9VlAkwaOJQZVaCcR-EFiiFVDwxPGOg3y1HwqETA4aGykwWRmGshE2tCSJlI3jvBXIxARsTDb9J_GVzv4OV11POuzydIEoHNXdaCWMi0NvI_WDrLHQtA_7Gc_8M1_zNZ-uOwtH1_3kTb5BrHQGnb1rE3CQ7prhFLrctOde3yY--QKPRdC6wv9kUNG5NRU0LmKwPgKwwZp-e4K0GxbSQFdB1TXW1PKYr5wOpKVgCFNAwL_3FtGxKvS7EfKZom-y2pqWli7bKBxWFprIsDJ2bRmB2FwyTmCjQUIWArO6Qz-eyHXfJbgG_e5_QIU-0loIBzIBYaymBjoMBKAPLAq2Z9EjYy0-uupLu2FnkJHehBVGatzKXg8zlTubywCMvNt_plnrm6LcolpuRWIzcfVBWx3mn23KgeCyIA2uiIZbvl0BpYWUp10JbJZTxyF4vjXmnIev8VBQ98nTzGHQbOqxEYcqlGwMvBkKZeuRei4HNTCLXSoENPZJsoWNrqttPitnU1U9Pmat66JGXPY5Op_XvrXhw9iqekCsApfzjwfjwIbnKEOVYfpXvkd2mWppH5JJaNbO6euzUBCVfzxtSvwAgAaiQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Engineered+macrophages+as+near-infrared+light+activated+drug+vectors+for+chemo-photodynamic+therapy+of+primary+and+bone+metastatic+breast+cancer&rft.jtitle=Nature+communications&rft.au=Huang+Yanjuan&rft.au=Guan+Zilin&rft.au=Dai+Xiuling&rft.au=Shen+Yifeng&rft.date=2021-07-14&rft.pub=Nature+Publishing+Group&rft.eissn=2041-1723&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41467-021-24564-0&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |